Drug details

Trikafta (lexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)

type of CFTR Potentiators, CFTR Correctors

Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor used to treat cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.

The drug is often used to treat Cystic fibrosis .

This drug may have the following side effects:

• yellowing of the skin or eyes (jaundice)
• loss of appetite,
• dark urine, and
• hives, 
• difficulty breathing, 
• swelling of your face, lips, tongue, or throat, 
• stomach pain (upper right side), 
• vision changes, 

The following drugs are related to Trikafta, either as a replacement or used together:

• Cayston (aztreonam for inhalation solution)
• Bronchitol (mannitol inhalation powder, for oral inhalation use)
• Pulmozyme (dornase alfa)
• Kalydeco (ivacaftor)
• Orkambi (lumacaftor and ivacaftor film-coated tablets for oral administration)
• Symdeko (tezacaftor/ivacaftor tablets and ivacaftor tablets)